Categories AlphaGraphs, Earnings, Technology

Facebook’s Q2 results beat market estimates

Facebook Inc. (NASDAQ: FB) beat market expectations for both revenue and earnings in the second quarter of 2019, sending the stock climbing 1.4% in after-market hours on Wednesday.

Total revenues were $16.8 billion, up 28% from the same period last year, and ahead of estimates of $16.5 billion.  

Facebook beats market estimates on revenue and earnings for second quarter 2019

Net income grew 48% year-over-year to $2.6 billion or $0.91 per share. Excluding a one-time legal expense and income tax expenses, adjusted EPS would have been $1.99. Analysts had forecast EPS of $1.87.

Advertising revenues, which make up the majority of Facebook’s revenues, increased 28% year-over-year to $16.6 billion. Mobile advertising revenue represented approx. 94% of advertising revenue, up from approx. 91% of advertising revenue in the year-ago quarter. Revenue from payments and other fees rose 36% to $262 million.

Daily Active Users (DAUs) increased 8% year-over-year to 1.59 billion. Monthly Active Users (MAUs) also rose 8% to 2.41 billion.

Total costs and expenses increased 66% to $12.2 billion. Operating margin dropped to 27% in the second quarter from 44% in the year-ago period.

Facebook has been handed a record $5 billion fine by the Federal Trade Commission (FTC) over the company’s privacy policies. The settlement with the FTC also requires Facebook to create an independent privacy committee on its board of directors to remove unfettered control by Zuckerberg over decisions regarding user privacy. In the second quarter, Facebook recorded an additional $2 billion accrual in connection with its settlement with the FTC.

Facebook’s rival Snap Inc. (NASDAQ: SNAP) reported second quarter 2019 results on Tuesday, beating estimates. Another competitor Twitter Inc. (NYSE: TWTR) is set to report Q2 results on Friday.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top